Novartis Investigative Site

Taichung, Taiwan 40705

0 studies enrolling now · 11 studies all time

What they study most

Adenocarcinoma, Carcinoma, Cardiovascular Disease, Chronic Heart Failure, Dyslipidaemia, Heart Failure With Reduced Ejection Fraction, Hepatitis C, Hypernephroid, Hypertension, Nephroid Carcinoma, Renal Cell, Rheumatoid Arthritis

Studies at this site

• Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer — Completed
• Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure — Completed
• Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants — Completed
• Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. — Completed
• This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure — Stopped early
• Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension — Completed
• Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension — Completed
• Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX) — Completed
• Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) — Stopped early
• 8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension — Completed
• Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients — Completed